



ASX ANNOUNCEMENT

1H FY26 Results - Investor Briefing Invitation

MELBOURNE, Australia (3 March 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has today released an investor presentation relating to its 1H FY26 results, which were announced on Friday, 27 February 2026. A copy of the presentation is attached to this announcement.

Investors are also reminded that the Company will host a webinar today, Tuesday, 3 March 2026 at 11.00am (AEDT).

Participants can pre-register ahead of time via the following link:

https://us02web.zoom.us/webinar/register/WN_cf43dYzuQOSjSTNAyNHBZA

Once the registration form is completed, investors will receive a confirmation email with details on how to access the meeting.

The Lumos team looks forward to welcoming those shareholders and potential investors who are able to attend.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598

For personal use only



Lumos Diagnostics Holdings Limited

1H FY26 Results Presentation

3 March 2026

Financial information is shown in USD unless otherwise stated.

www.lumosdiagnostics.com

ersonal use only

Disclaimer and Important Information



This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company).

The information contained in this document ("Document") has been prepared by Lumos Diagnostics Holdings Limited (referred to as "Lumos" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Lumos periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein.

The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or

representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast. The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Lumos business and markets. Such information is generally based on independent market and industry data or research. Lumos has not independently verified and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.


The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Non-IFRS financial measures

Recipients should note that certain financial data included in this Document is not recognised under the AAS and is classified as 'non-IFRS financial information' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. The Company believes that this non-IFRS financial information provides useful information to users in measuring the financial performance and condition of Lumos. The non-IFRS financial measures do not have standardised meanings under AAS, and therefore may not be comparable with similarly titled measures presented by other entities, nor should these be interpreted as an alternative to other financial measures determined in accordance with AAS. Investors are cautioned not to place undue reliance on any non-IFRS financial information, ratios and metrics included in this Document.

Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, **at the point-of-care.**

Lumos Business Overview



People and Capability drive value - able to leverage R&D, IP, manufacturing scale, medical, quality and regulatory skillset across Lumos' Products and Commercial Services business.

Pivotal Milestones Achieved in 1H FY26



Securing pivotal U.S. exclusive distribution agreement with PHASE Scientific for US\$317m for FebriDx®.



Completion of FebriDx® CLIA waiver clinical study and submission to U.S. FDA.



Achieved 100% Medicare reimbursement recognition across all seven U.S. MAC jurisdictions.



Commencement of the BARDA funded CLIA waived paediatric (patients 2 to 12 years) clinical study for FebriDx® in the U.S.




Establishment of A\$5.0m loan facility to enable access to working capital to anticipated CLIA waiver for FebriDx®.

Positive operating cash flow of \$0.8m - improvement of \$7.1m over the pcp.

Includes \$2.8m non-dilutive grant funding received from BARDA.

Financial Summary – Half Year


Revenue (\$M)



Commentary

- **1H FY26 revenue of \$6.1M** was as expected and has a positive change in the revenue mix.
- **Products revenue of \$1.7M** v's \$0.8M in pcp (up 100%), largely FebriDx revenue (up 144x pcp), with FebriDx revenue more than offsetting the discontinued ViraDx sales.
- **Services revenue of \$4.4M** v's \$5.5M in pcp (down 19%). Reduction was due to the lower Hologic IP revenue recognised in the 1H FY26 of \$1.0M v's \$2.6M in the pcp. Large portion backfilled with ongoing project work.

Gross Profit (\$M) & Margin



Commentary


- **1H FY26 gross profit of \$4.2M** in line with the pcp, despite the lower revenue.
- **Gross profit margin of 68%**, an improvement of 1% over the pcp. Up 13% since 1H FY24.

Financial Summary – Half Year

Adjusted EBITDA* (\$M)



Net Cashflow Generation (\$M)*



Commentary

- **1H FY26 Adjusted EBITDA loss of \$1.4M** v's a loss of \$0.9M in the pcp.
- **OPEX was \$8.0M** v's \$6.1M in pcp. Comments:
 - FebriDx CLIA and paediatric trial costs (note, these are offset by BARDA grant receipts)
 - Increased sales & marketing spend, particularly for FebriDx in the US
 - Some new staff hires and higher medical insurance costs

Commentary

- **1H FY26 operating cashflow** was a positive cash inflow of \$0.8M, an improvement of \$7.1M over the pcp
- **Non-dilutive BARDA funding** cash receipts of \$2.8M
- **Payments for PP&E** continue to be minimal
- **Net cashflow generation of \$0.1M**, significantly improved over outflows of \$6.8M and \$5.5M in FY25 and FY24
- **Cash at bank** at 31 December 2025 of \$3.0M
- **Finance facility** of A\$4.0M (\$2.8M) remains available

*Adjusted EBITDA excludes share-based payments and one-off impairments and expenses.
© Lumos Diagnostics™. All rights reserved.

*Net cash generation comprised of operating and investing cash flow, plus lease payments.

Key Priorities



FDA decision on the CLIA waiver for FebriDx® is expected by end March 2026 or earlier.



Implement agreement with PHASE Scientific, advance national payer coverage through our partnerships with Pro-spectus and AcuityMD, and plan for volume scale-up.



Progress FebriDx paediatric study – fully funded with \$6.2M by BARDA - addresses important clinical market for 2 -12 yr olds and expands U.S. market by approx. 20%.



Deliver on Hologic fFN development milestones - additional milestone 3 studies from Phase 2 & Phase 3 milestones 4 - 9.



Progress to formal product development on the first Lumos branded women's health diagnostics test.

Investor Takeaways



First in Class Product FebriDx® Nearing Major US Breakthrough

- CLIA waiver study exceeded performance targets (99%+ concordance)
- FDA submission lodged 18 Aug 2025, decision expected by end March 2026
- FebriDx® protected by a broad global patent estate covering method, device, and biomarkers



> US\$1.0 Billion p.a. TAM for FebriDx

- CLIA waiver unlocks >80M patient interactions annually in the US
- 0442U: proprietary PLA Code assigned for FebriDx®
- CMS established rate on CLFS (Clinical Lab Fee Schedule) for FebriDx at \$41.38 per test
- 100% Medicare reimbursement achieved across all 7 MACs. Focus shifts to private payors



Transformational US\$317M (A\$487M) Distribution Deal

- With PHASE Scientific for the US market over 6 years,¹ assuming FebriDx® granted CLIA waiver and minimum order quantities (MOQ's) are achieved
- Initial \$5M prepaid order triggered at CLIA waiver grant
- One of the largest POC distribution deals for an ASX-listed diagnostics company



Commercial Services Division

- Licensing/IP agreements add recurring high-margin revenue
- Hologic: \$10M IP licensing + \$7.0M development agreement for next-gen fFN women's health test
- Additional \$1.9M Aptatek contract advancing in-home PKU monitoring



Underlying Financials Performance Improving

- 1H FY26 revenue of \$6.1M.
- 1H FY26 FebriDx US revenue of \$1.4M, up 144x on the pcp
- 1H FY26 gross profit steady with a margin of 68%, 1% improvement on pcp
- Positive net operating cashflow generation in 1H FY26



Strong Funding Partnerships, No Royalties Payable

- BARDA: \$8.3M non-dilutive funding (CLIA waiver + paediatric studies)
- A\$4.0M loan facility available with Tenmile and Ryder Capital (drawdowns at Lumos discretion)

ersonal use only



Thank You

www.lumosdiagnostics.com